News & Updates

Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.

Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.

Consuming foods with emulsifiers may increase the risk of cardiovascular disease (CVD) as shown in a large prospective cohort study.

Use of calcium-channel blockers (CCBs) appears to increase the risk of developing glaucoma, suggests a study. In addition, use of systemic beta blockers is associated with lower intraocular pressure (IOP).

Older adults with hypertension who are on blood pressure (BP)-lowering medications are better protected against dementia than those with untreated hypertension, and this is true across all ages in late life, according to an individual participant data meta-analysis.

Two studies presented at ERS 2023 demonstrated the potential of a continuous positive airway pressure (CPAP) machine to address cardiovascular (CV) risks in individuals with obstructive sleep apnoea (OSA).